Faculté de médecine, Université de Sherbrooke
Sherbrooke, Quebec, J1H 5N4, Canada
NCT Number: NCT00156585
Hypothesis: the pattern of MRI contrast enhancement after gadolinium injection is different in tumors that respond well to gamma knife.
We are going to acquire sequential T1-weighted images of brain lesions before, during and after injection of Gd-DTPA. This will be repeated before and after a treatment with gamma knife. We will then analyse our results to see if there are common enhancement characteristics between lesions that will respond well to the radiosurgery treatment. Response will be clinically assessed by tumor volume as determined by MRI approximately 4 to 6 months after treatment.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Sherbrooke, Quebec, J1H 5N4, Canada
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Before treatment with the Gamma Knife
Tumor volume, Ktrans, ve, time at maximum signal enhancement, maximum signal difference, ADC, basal T1 value
Martin Lepage
Other
Prospective Study of Predictive Value of Dynamic Contrast Enhancement Magnetic Resonance Imaging With Gadolinium on the Response of a Cerebral Tumor to a Treatment With Gamma Knife
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02022800
Cerebral Metastases, Glioma
Nice, France
View Trial DetailsNCT04807582
Cerebral Metastases
London, United Kingdom
View Trial DetailsNCT06710249
Astrocytoma, Brain Diseases
Lund, Sweden
View Trial Details